SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Jack Russell who wrote (12733)3/20/2014 9:09:10 PM
From: Mark Buczynski  Respond to of 13111
 
Good find. I remember hearing about or talking about their interest in acquisition. Basically, I remember something akin to 'no company has enough money to pay us what we're worth'. This is again something a vaguely remember, and I could be all wrong.

Nice attitude to have, if you have strong enough tech. I believe their tech is unmatched.



To: Jack Russell who wrote (12733)3/20/2014 10:07:24 PM
From: Mark Buczynski  Read Replies (1) | Respond to of 13111
 
From your post and the article -

.” That means Heidecker will be looking at companies working on drugs in fields like dermatology, opthamology and regenerative medicine, as well as therapeutic vaccines aimed at cancers. "

Well gee, the part about cancer vaccine - that kind of narrows down their focus like a laser beam. There's not too many companies making that claim...


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News